|
Jul 31
|
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
|
|
Jul 25
|
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
|
|
Jul 19
|
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
|
|
Jun 21
|
Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024
|
|
Jun 21
|
Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024
|
|
Jun 18
|
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)
|
|
Apr 3
|
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
|
|
Apr 1
|
Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript
|
|
Mar 18
|
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
|
|
Mar 13
|
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
|
|
Feb 15
|
Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
|
|
Jan 10
|
Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
|
|
Dec 20
|
Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
|
|
Dec 4
|
Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
|
|
Oct 27
|
Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls
|
|
Jun 24
|
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
|